Bristol-Myers Squibb Company (BMY) 60.04 $BMY
3 Stocks That Were Huge Winners Last Week
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 14, 11:29AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. The market's best-performing companies last week included...
JNJ: 99.62 (+1.18), BIIB: 391.66 (-0.45), PTLA: 34.96 (+3.13), SHPG: 239.82 (+6.11), PFE: 34.64 (-0.23), SGMO: 15.40 (+0.14), BMY: 60.04 (+0.56), MOH: 59.66 (+0.26)
Is This Company the Big Winner in Obama's Push for Precision Medicine?
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 14, 8:56AM CST
Source: Illumina Inc. President Obama has released more details about his plans to fund a precision medicine initiative that the administration hopes will mean that doctors can deliver the right medicine to the right patient at the right dose ...
JNJ: 99.62 (+1.18), BMRN: 100.76 (+1.98), AZN: 69.96 (+0.20), ILMN: 198.54 (+1.81), BMY: 60.04 (+0.56), SNY: 49.42 (+0.82)
Game-Changing News: Researchers May Have Discovered the Cause of Intestinal Cancer
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 14, 8:12AM CST
Source: Flickr user Erik Soderstrom. Cancer is currently the second-leading cause of death in the United States, and if the World Health Organization is correct, it may wind up eclipsing heart disease for the dubious top spot sometime in the near...
AZN: 69.96 (+0.20), EXAS: 25.56 (-0.54), BMY: 60.04 (+0.56)
A Dividend Investor's Dilemma: Take Profits Or Let It Ride?
Parsimony Investment Research - at Seeking Alpha - Fri Feb 13, 7:34PM CST
DPS: 76.95 (-1.35), HD: 111.89 (-0.27), WBA: 78.73 (-1.23), LB: 94.51 (-0.30), TXN: 57.97 (+0.53), TGT: 76.12 (-0.75), WSM: 82.11 (+0.73), MO: 54.76 (-0.78), GLW: 25.00 (+0.14), BMY: 60.04 (+0.56), AAPL: 127.08 (+0.62)
1 Sentence That Tells You Everything You Need to Know About Each of These 10 Big Pharma Earnings Rep
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 13, 7:02AM CST
Source: AstraZeneca. Earnings season is more than halfway over, and it hasn't been easy to keep pace with hundreds upon hundreds of earnings reports, sometimes all hitting within the same day. Much of the healthcare sector, especially big...
BIIB: 391.66 (-0.45), JNJ: 99.62 (+1.18), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16)
Analysis of Chinese Liver Disease Drug Industry 2015
M2 - Fri Feb 13, 5:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/lh55pz/analysis_of) has announced the addition of the "Analysis of Chinese Liver Disease Drug Industry 2015" report to their offering. Liver disease drug market competition in China is fierce. China's liver disease drug market can be divided into imported drugs and home-made drugs according to the drug producing area. Imported drugs are mainly represented by GlaxoSmithKline and Bristol-Myers Squibb, etc.; the main production enterprises of home-made drugs include Chia Tai Tianqing Pharmaceutical Group, TIPR Pharmaceutical Responsible Company, Fujian Cosunter Pharmaceutical Company, etc. Hepatobiliary system drug has gradually become a variety that costs a large amount of money and it is the third largest one that ranks only second to anti-peptic ulcer and diabetes drug in the digestion metabolism category. In terms of the structure of drug, anti-viral drugs and free regulating drugs account for 30% of liver disease drug, auxiliary drugs account for 25% and Chinese medicine account for 36%. The sales volume of China liver disease drug in hospital market is increasing. Before 2009, as a result of the continuous introduction of new products, new specifications and new dosage form products, the growth of sales was comparatively large, while its growth began to slow down from 2010. On the one hand, it is due to the hepatitis B vaccination rate has been increased significantly in recent years and the decrease of the expansion speed of hepatitis B patients; on the other hand, the growth of sales has entered a smooth stage. The data issued by China Competition Information shows that, the scale of China liver disease drug market is close to RMB 43 billion in 2013. Key Topics Covered: CHAPTER I RELATED OVERVIEW OF LIVER DISEASE DRUG CHAPTER II ANALYSIS OF THE OPERATION SITUATION OF GLOBAL DRUGS FOR THE LIVER DISEASE MARKETS IN 2013 CHAPTER III ANALYSIS OF MARKET DEVELOPMENT ENVIRONMENT OF CHINA'S LIVER DISEASE DRUG INDUSTRY IN 2013-2014 SECTION IV THE LEVEL AND FEATURES OF LIVER DISEASE MEDICATION TECHNIQUE CHAPTER IV HEPATITIS INCIDENCE IN CHINA AND ANALYSIS OF THE STATISTICS OF ITS PREVALENCE IN 2013 CHAPTER V TYPES OF LIVER MEDICINE CHAPTER VI DEEP RESEARCH OF CHINA LIVER MEDICATION MARKET IN 2013 CHAPTER VII OBSERVATION ON DYNAMICS OF SEGMENT MARKET OF LIVER DISEASE DRUGS 2013 CHAPTER VIII CHINA HEPATITIS B VACCINE MARKET ANALYSIS IN 2013 CHAPTER IX COMPARATIVE ANALYSIS OF MAIN ANTI-HEPATITIS DRUGS IN CHINA IN 2012-2013 CHAPTER X CLINICAL APPLICATION OF LIVERISH RESEARCH RESULTS AND DYNAMIC TRACING OF THE NEWEST CHAPTER XI ANALYSIS OF DYNAMIC AND TREND COMPETITION FOR CHINA'S LIVER DISEASE DRUG MARKET IN 2013 CHAPTER XII SWOT ANALYSIS OF CHINA'S LIVER DISEASE DRUG MARKET IN 2013 CHAPTER XIII ANALYSIS OF OPERATION CONDITIONS OF TYPICAL DOMESTIC AND FOREIGN DRUGS PRODUCTION CHAPTER XIV MARKET DEVELOPING PROSPECTS AND TRENDS ON CHINA'S MEDICATIONS FOR HEPATOPATHY FROM 2015 TO 2020 CHAPTER XV RESEARCH AND ANALYSIS OF CHINA'S LIVER DISEASE DRUG MARKET INVESTMENT FEASIBILITY FROM 2015 TO 2020 Companies Mentioned - AMERICAN MERCK & CO - Beijing Sl Pharmaceutical Co., Ltd. - Bristol-Myers Squibb - Chia Tai Tianqing Pharmaceutical Group Co. Ltd. - Fujian Cosunter Pharmaceutical Co. Ltd. - GlaxoSmithKline - Inner Mongolia Furui Medical Science Co. Ltd. - ROCHE - TIPR Pharmaceutical Responsible Company For more information visit http://www.researchandmarkets.com/research/lh...nalysis_of
GSK: 47.94 (+1.99), BMY: 60.04 (+0.56)
Jim Cramer's 'Mad Money' Recap: Get Ready to Profit on Europe-Induced Weakness
at The Street - Wed Feb 11, 7:14PM CST
Lots of investors are worried about Europe, Cramer says, but you don't have to be.
KMI: 41.97 (+0.21), ACHC: 63.20 (-0.45), FLEX: 12.05 (-0.09), GE: 25.15 (+0.26), BBT: 38.28 (-0.04), AWAY: 29.68 (+0.11), XOM: 93.37 (+1.00), KEY: 14.11 (-0.08), INTC: 34.36 (+0.23), AFFX: 11.45 (+0.02), TWX: 83.87 (+0.56), PEP: 99.13 (-1.14), AEP: 57.83 (-0.15), ETP: 60.17 (+0.96), CMG: 674.89 (+4.60), QLYS: 47.95 (+1.46), GOOGL: 551.16 (+5.15), MSFT: 43.87 (+0.78), HSIC: 143.18 (+0.72), AAPL: 127.08 (+0.62), REGN: 402.40 (+0.66), CSCO: 29.43 (-0.03), CY: 14.76 (+0.01), SWKS: 81.85 (-0.57), PWR: 28.76 (-0.10), FB: 75.74 (-0.49), PFE: 34.64 (-0.23), HAL: 44.19 (+1.42), AMGN: 153.48 (+0.30), BAC: 16.61 (-0.06), BMY: 60.04 (+0.56), BA: 149.73 (+1.64), HPQ: 38.56 (+0.19), RAD: 8.34 (+0.25), CELG: 115.88 (+0.16), ZTS: 45.46 (-0.33), UA: 73.76 (-0.19), AA: 15.81 (+0.16), GILD: 101.90 (+1.10), STI: 41.57 (+0.01), GM: 37.62 (-0.40), AGIO: 118.55 (+0.11), CRL: 73.61 (-0.33), FSL: 37.53 (+2.83), VIAB: 68.98 (+1.27), CL: 70.08 (+0.23)
Analyzing the Global Pharmaceutical Industry 2015
M2 - Wed Feb 11, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvx6qs/analyzing_the) has announced the addition of the "Analyzing the Global Pharmaceutical Industry 2015" report to their offering. This report presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018. The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy - store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat. We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry. An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018. Key Topics Covered: Section 1: Analyzing the Global Pharmaceutical Industry Section 2: Analyzing the Global Pharmaceutical Markets Section 3: Analyzing the Major Market Players Section 4: Glossary of Terms Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Amgen, Inc. - Astellas Pharma - AstraZeneca - Aurobindo Pharma Ltd - Baxter International - Bayer AG - Boehringer Ingelheim - Bristol-Myers Squibb - Cadila Healthcare - Chiesi Farmaceutici SpA - Dr. Reddy's Laboratories Limited - Eisai Co., Ltd - Eli Lilly and Company - F. Hoffmann-La Roche - GlaxoSmithKline Plc - Jiangsu Yangtze River Pharmaceutical Group Co., Ltd. - Johnson & Johnson - Jubilant Life Sciences Ltd - Lupin Limited - Merck & Co. - Mylan Laboratories Ltd - Novartis AG - Pfizer - Sanofi SA - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - Yunnan Baiyao Group For more information visit http://www.researchandmarkets.com/research/jv...lyzing_the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), BAX: 70.39 (+0.31), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Seattle Genetics Posts Narrower-than-Expected Loss in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 8:18AM CST
Seattle Genetics, Inc. (SGEN) reported a loss of 22 cents per share, narrower than the Zacks Consensus Estimate of a loss of 27 cents.
BMRN: 100.76 (+1.98), SGEN: 31.57 (+0.36), BMY: 60.04 (+0.56)
Seattle Genetics, Inc. Exceeds Expecations
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 10, 6:42PM CST
Seattle Genetics rounded out 2014 with revenue a hair above the guidance it gave last quarter. For the year, the biotech registered $178.2 million in sales of its blood cancer drug Adcetris in the U.S. and Canada, just above the $177 million upper...
SGEN: 31.57 (+0.36), BMY: 60.04 (+0.56)
Will Pfizer Inc. Break Up in 2015?
George Budwell, The Motley Fool - Motley Fool - Tue Feb 10, 11:59AM CST
Source: Flickr via user William Murphy. Pfizer is the world's largest drugmaker, reporting nearly $50 billion in sales last year. Even so, its stock has drastically underperformed the broader market over the past decade: The pharma...
ZTS: 45.46 (-0.33), ACT: 285.37 (+3.71), PFE: 34.64 (-0.23), ABBV: 58.05 (+1.00), BMY: 60.04 (+0.56)
Data Analytics Is Good Business - Cramer's Lightning Round (2/9/15)
SA Editor Mohit Manghnani - Seeking Alpha - Tue Feb 10, 5:36AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, February 9. Bullish Calls: Bristol-Myers Squibb (NYSE: BMY ): " Bristol-Myers is fine. You need to take a long-term view on it." Frontier...
STR: 24.09 (-0.08), VRSK: 67.90 (+0.46), IBM: 160.40 (+1.88), NUE: 48.90 (+0.55), TAL: 41.00 (+0.37), BMY: 60.04 (+0.56), DATA: 99.90 (+1.40), X: 26.36 (+1.12)
Jim Cramer's Top Stock Picks: TWTR BMY NUE WFC
at The Street - Tue Feb 10, 5:00AM CST
Cramer says Twitter insiders should stop selling for now and Wells Fargo is his favorite financial.
NUE: 48.90 (+0.55), WFC: 55.33 (+0.47), BMY: 60.04 (+0.56), TWTR: 48.50 (+0.55)
'Mad Money' Lightning Round: Take Nucor Over United States Steel
at The Street - Tue Feb 10, 5:00AM CST
Cramer continues to recommend Bristol-Myers Squibb but wants you to be careful on TAL International.
FTR: 8.38 (+0.01), VRSK: 67.90 (+0.46), NUE: 48.90 (+0.55), TAL: 41.00 (+0.37), BMY: 60.04 (+0.56), X: 26.36 (+1.12)
Jim Cramer's 'Mad Money' Recap: Stop Worrying About the Fed Rate Increase
at The Street - Mon Feb 09, 7:53PM CST
History tells us that growth and progress are positives for the stock market, Cramer says, and this time will be no different.
FTR: 8.38 (+0.01), NUE: 48.90 (+0.55), WFC: 55.33 (+0.47), BMY: 60.04 (+0.56), XLU: 45.17 (-0.70), AB: 27.17 (+0.47), VRSK: 67.90 (+0.46), RIG: 19.05 (+0.42), GILD: 101.90 (+1.10), MPC: 103.48 (+2.08), MRO: 29.49 (+0.71), TAL: 41.00 (+0.37), TWTR: 48.50 (+0.55), X: 26.36 (+1.12)
Bristol-Myers Squibb Set to Possibly Rebound After Yesterday's Selloff of 1.37%
Comtex SmarTrend(R) - Mon Feb 09, 4:16PM CST
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $58.65 to a high of $59.75. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $58.76 on volume of 3.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BMY: 60.04 (+0.56)
SmarTrend Watching for Potential Rebound in Shares of Bristol-Myers Squibb After 1.37% Loss
Comtex SmarTrend(R) - Mon Feb 09, 4:16PM CST
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $58.65 to a high of $59.75. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $58.76 on volume of 3.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BMY: 60.04 (+0.56)
AstraZeneca Might Need More Than Buzzwords To Bridge The Gap
EP Vantage - Seeking Alpha - Mon Feb 09, 1:57PM CST
It is widely appreciated that life is going to get tougher for AstraZeneca (NYSE: AZN ) over the next couple of years as huge patent expiries bite chunks out of its top line. As the company would have it, however, profits will remain far more...
ACT: 285.37 (+3.71), AZN: 69.96 (+0.20), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17)
3 Medical Advancements You May Be Missing Out On
Motley Fool Staff - Motley Fool - Sun Feb 08, 10:02AM CST
Source: 3D Systems. From 3D printing to next-generation cancer killers, there are some medical innovations that could have an incredible impact on patients. Our Motley Fool analysts explain how these next-generation medical advances could reshape...
BIIB: 391.66 (-0.45), ONVO: 6.34 (+0.07), DDD: 32.81 (+0.40), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17), CELG: 115.88 (+0.16)
Which Biotech Stock Should Pfizer, Inc. Buy?
Motley Fool Staff, Brian Orelli, Leo Sun, and George Budwell - Motley Fool - Sun Feb 08, 7:02AM CST
Source: Pfizer. Pfizer is struggling to offset slowing sales tied to expiring patents, and that has some observers thinking that Pfizer remains on the hunt to buy another drugmaker that can spark its growth. Earlier this week, Pfizer announced...
BIIB: 391.66 (-0.45), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), CLDN: 16.45 (-0.05), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16), SGEN: 31.57 (+0.36), GILD: 101.90 (+1.10), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07)
3 Stocks That Were Huge Winners Last Week
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 14, 11:29AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. The market's best-performing companies last week included...
JNJ: 99.62 (+1.18), BIIB: 391.66 (-0.45), PTLA: 34.96 (+3.13), SHPG: 239.82 (+6.11), PFE: 34.64 (-0.23), SGMO: 15.40 (+0.14), BMY: 60.04 (+0.56), MOH: 59.66 (+0.26)
Is This Company the Big Winner in Obama's Push for Precision Medicine?
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 14, 8:56AM CST
Source: Illumina Inc. President Obama has released more details about his plans to fund a precision medicine initiative that the administration hopes will mean that doctors can deliver the right medicine to the right patient at the right dose ...
JNJ: 99.62 (+1.18), BMRN: 100.76 (+1.98), AZN: 69.96 (+0.20), ILMN: 198.54 (+1.81), BMY: 60.04 (+0.56), SNY: 49.42 (+0.82)
Game-Changing News: Researchers May Have Discovered the Cause of Intestinal Cancer
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 14, 8:12AM CST
Source: Flickr user Erik Soderstrom. Cancer is currently the second-leading cause of death in the United States, and if the World Health Organization is correct, it may wind up eclipsing heart disease for the dubious top spot sometime in the near...
AZN: 69.96 (+0.20), EXAS: 25.56 (-0.54), BMY: 60.04 (+0.56)
A Dividend Investor's Dilemma: Take Profits Or Let It Ride?
Parsimony Investment Research - at Seeking Alpha - Fri Feb 13, 7:34PM CST
DPS: 76.95 (-1.35), HD: 111.89 (-0.27), WBA: 78.73 (-1.23), LB: 94.51 (-0.30), TXN: 57.97 (+0.53), TGT: 76.12 (-0.75), WSM: 82.11 (+0.73), MO: 54.76 (-0.78), GLW: 25.00 (+0.14), BMY: 60.04 (+0.56), AAPL: 127.08 (+0.62)
1 Sentence That Tells You Everything You Need to Know About Each of These 10 Big Pharma Earnings Rep
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 13, 7:02AM CST
Source: AstraZeneca. Earnings season is more than halfway over, and it hasn't been easy to keep pace with hundreds upon hundreds of earnings reports, sometimes all hitting within the same day. Much of the healthcare sector, especially big...
BIIB: 391.66 (-0.45), JNJ: 99.62 (+1.18), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16)
Analysis of Chinese Liver Disease Drug Industry 2015
M2 - Fri Feb 13, 5:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/lh55pz/analysis_of) has announced the addition of the "Analysis of Chinese Liver Disease Drug Industry 2015" report to their offering. Liver disease drug market competition in China is fierce. China's liver disease drug market can be divided into imported drugs and home-made drugs according to the drug producing area. Imported drugs are mainly represented by GlaxoSmithKline and Bristol-Myers Squibb, etc.; the main production enterprises of home-made drugs include Chia Tai Tianqing Pharmaceutical Group, TIPR Pharmaceutical Responsible Company, Fujian Cosunter Pharmaceutical Company, etc. Hepatobiliary system drug has gradually become a variety that costs a large amount of money and it is the third largest one that ranks only second to anti-peptic ulcer and diabetes drug in the digestion metabolism category. In terms of the structure of drug, anti-viral drugs and free regulating drugs account for 30% of liver disease drug, auxiliary drugs account for 25% and Chinese medicine account for 36%. The sales volume of China liver disease drug in hospital market is increasing. Before 2009, as a result of the continuous introduction of new products, new specifications and new dosage form products, the growth of sales was comparatively large, while its growth began to slow down from 2010. On the one hand, it is due to the hepatitis B vaccination rate has been increased significantly in recent years and the decrease of the expansion speed of hepatitis B patients; on the other hand, the growth of sales has entered a smooth stage. The data issued by China Competition Information shows that, the scale of China liver disease drug market is close to RMB 43 billion in 2013. Key Topics Covered: CHAPTER I RELATED OVERVIEW OF LIVER DISEASE DRUG CHAPTER II ANALYSIS OF THE OPERATION SITUATION OF GLOBAL DRUGS FOR THE LIVER DISEASE MARKETS IN 2013 CHAPTER III ANALYSIS OF MARKET DEVELOPMENT ENVIRONMENT OF CHINA'S LIVER DISEASE DRUG INDUSTRY IN 2013-2014 SECTION IV THE LEVEL AND FEATURES OF LIVER DISEASE MEDICATION TECHNIQUE CHAPTER IV HEPATITIS INCIDENCE IN CHINA AND ANALYSIS OF THE STATISTICS OF ITS PREVALENCE IN 2013 CHAPTER V TYPES OF LIVER MEDICINE CHAPTER VI DEEP RESEARCH OF CHINA LIVER MEDICATION MARKET IN 2013 CHAPTER VII OBSERVATION ON DYNAMICS OF SEGMENT MARKET OF LIVER DISEASE DRUGS 2013 CHAPTER VIII CHINA HEPATITIS B VACCINE MARKET ANALYSIS IN 2013 CHAPTER IX COMPARATIVE ANALYSIS OF MAIN ANTI-HEPATITIS DRUGS IN CHINA IN 2012-2013 CHAPTER X CLINICAL APPLICATION OF LIVERISH RESEARCH RESULTS AND DYNAMIC TRACING OF THE NEWEST CHAPTER XI ANALYSIS OF DYNAMIC AND TREND COMPETITION FOR CHINA'S LIVER DISEASE DRUG MARKET IN 2013 CHAPTER XII SWOT ANALYSIS OF CHINA'S LIVER DISEASE DRUG MARKET IN 2013 CHAPTER XIII ANALYSIS OF OPERATION CONDITIONS OF TYPICAL DOMESTIC AND FOREIGN DRUGS PRODUCTION CHAPTER XIV MARKET DEVELOPING PROSPECTS AND TRENDS ON CHINA'S MEDICATIONS FOR HEPATOPATHY FROM 2015 TO 2020 CHAPTER XV RESEARCH AND ANALYSIS OF CHINA'S LIVER DISEASE DRUG MARKET INVESTMENT FEASIBILITY FROM 2015 TO 2020 Companies Mentioned - AMERICAN MERCK & CO - Beijing Sl Pharmaceutical Co., Ltd. - Bristol-Myers Squibb - Chia Tai Tianqing Pharmaceutical Group Co. Ltd. - Fujian Cosunter Pharmaceutical Co. Ltd. - GlaxoSmithKline - Inner Mongolia Furui Medical Science Co. Ltd. - ROCHE - TIPR Pharmaceutical Responsible Company For more information visit http://www.researchandmarkets.com/research/lh...nalysis_of
GSK: 47.94 (+1.99), BMY: 60.04 (+0.56)
Jim Cramer's 'Mad Money' Recap: Get Ready to Profit on Europe-Induced Weakness
at The Street - Wed Feb 11, 7:14PM CST
Lots of investors are worried about Europe, Cramer says, but you don't have to be.
KMI: 41.97 (+0.21), ACHC: 63.20 (-0.45), FLEX: 12.05 (-0.09), GE: 25.15 (+0.26), BBT: 38.28 (-0.04), AWAY: 29.68 (+0.11), XOM: 93.37 (+1.00), KEY: 14.11 (-0.08), INTC: 34.36 (+0.23), AFFX: 11.45 (+0.02), TWX: 83.87 (+0.56), PEP: 99.13 (-1.14), AEP: 57.83 (-0.15), ETP: 60.17 (+0.96), CMG: 674.89 (+4.60), QLYS: 47.95 (+1.46), GOOGL: 551.16 (+5.15), MSFT: 43.87 (+0.78), HSIC: 143.18 (+0.72), AAPL: 127.08 (+0.62), REGN: 402.40 (+0.66), CSCO: 29.43 (-0.03), CY: 14.76 (+0.01), SWKS: 81.85 (-0.57), PWR: 28.76 (-0.10), FB: 75.74 (-0.49), PFE: 34.64 (-0.23), HAL: 44.19 (+1.42), AMGN: 153.48 (+0.30), BAC: 16.61 (-0.06), BMY: 60.04 (+0.56), BA: 149.73 (+1.64), HPQ: 38.56 (+0.19), RAD: 8.34 (+0.25), CELG: 115.88 (+0.16), ZTS: 45.46 (-0.33), UA: 73.76 (-0.19), AA: 15.81 (+0.16), GILD: 101.90 (+1.10), STI: 41.57 (+0.01), GM: 37.62 (-0.40), AGIO: 118.55 (+0.11), CRL: 73.61 (-0.33), FSL: 37.53 (+2.83), VIAB: 68.98 (+1.27), CL: 70.08 (+0.23)
Analyzing the Global Pharmaceutical Industry 2015
M2 - Wed Feb 11, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvx6qs/analyzing_the) has announced the addition of the "Analyzing the Global Pharmaceutical Industry 2015" report to their offering. This report presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018. The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy - store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat. We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry. An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018. Key Topics Covered: Section 1: Analyzing the Global Pharmaceutical Industry Section 2: Analyzing the Global Pharmaceutical Markets Section 3: Analyzing the Major Market Players Section 4: Glossary of Terms Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Amgen, Inc. - Astellas Pharma - AstraZeneca - Aurobindo Pharma Ltd - Baxter International - Bayer AG - Boehringer Ingelheim - Bristol-Myers Squibb - Cadila Healthcare - Chiesi Farmaceutici SpA - Dr. Reddy's Laboratories Limited - Eisai Co., Ltd - Eli Lilly and Company - F. Hoffmann-La Roche - GlaxoSmithKline Plc - Jiangsu Yangtze River Pharmaceutical Group Co., Ltd. - Johnson & Johnson - Jubilant Life Sciences Ltd - Lupin Limited - Merck & Co. - Mylan Laboratories Ltd - Novartis AG - Pfizer - Sanofi SA - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - Yunnan Baiyao Group For more information visit http://www.researchandmarkets.com/research/jv...lyzing_the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), BAX: 70.39 (+0.31), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Seattle Genetics Posts Narrower-than-Expected Loss in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 8:18AM CST
Seattle Genetics, Inc. (SGEN) reported a loss of 22 cents per share, narrower than the Zacks Consensus Estimate of a loss of 27 cents.
BMRN: 100.76 (+1.98), SGEN: 31.57 (+0.36), BMY: 60.04 (+0.56)
Seattle Genetics, Inc. Exceeds Expecations
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 10, 6:42PM CST
Seattle Genetics rounded out 2014 with revenue a hair above the guidance it gave last quarter. For the year, the biotech registered $178.2 million in sales of its blood cancer drug Adcetris in the U.S. and Canada, just above the $177 million upper...
SGEN: 31.57 (+0.36), BMY: 60.04 (+0.56)
Will Pfizer Inc. Break Up in 2015?
George Budwell, The Motley Fool - Motley Fool - Tue Feb 10, 11:59AM CST
Source: Flickr via user William Murphy. Pfizer is the world's largest drugmaker, reporting nearly $50 billion in sales last year. Even so, its stock has drastically underperformed the broader market over the past decade: The pharma...
ZTS: 45.46 (-0.33), ACT: 285.37 (+3.71), PFE: 34.64 (-0.23), ABBV: 58.05 (+1.00), BMY: 60.04 (+0.56)
Data Analytics Is Good Business - Cramer's Lightning Round (2/9/15)
SA Editor Mohit Manghnani - Seeking Alpha - Tue Feb 10, 5:36AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, February 9. Bullish Calls: Bristol-Myers Squibb (NYSE: BMY ): " Bristol-Myers is fine. You need to take a long-term view on it." Frontier...
STR: 24.09 (-0.08), VRSK: 67.90 (+0.46), IBM: 160.40 (+1.88), NUE: 48.90 (+0.55), TAL: 41.00 (+0.37), BMY: 60.04 (+0.56), DATA: 99.90 (+1.40), X: 26.36 (+1.12)
Jim Cramer's Top Stock Picks: TWTR BMY NUE WFC
at The Street - Tue Feb 10, 5:00AM CST
Cramer says Twitter insiders should stop selling for now and Wells Fargo is his favorite financial.
NUE: 48.90 (+0.55), WFC: 55.33 (+0.47), BMY: 60.04 (+0.56), TWTR: 48.50 (+0.55)
'Mad Money' Lightning Round: Take Nucor Over United States Steel
at The Street - Tue Feb 10, 5:00AM CST
Cramer continues to recommend Bristol-Myers Squibb but wants you to be careful on TAL International.
FTR: 8.38 (+0.01), VRSK: 67.90 (+0.46), NUE: 48.90 (+0.55), TAL: 41.00 (+0.37), BMY: 60.04 (+0.56), X: 26.36 (+1.12)
Jim Cramer's 'Mad Money' Recap: Stop Worrying About the Fed Rate Increase
at The Street - Mon Feb 09, 7:53PM CST
History tells us that growth and progress are positives for the stock market, Cramer says, and this time will be no different.
FTR: 8.38 (+0.01), NUE: 48.90 (+0.55), WFC: 55.33 (+0.47), BMY: 60.04 (+0.56), XLU: 45.17 (-0.70), AB: 27.17 (+0.47), VRSK: 67.90 (+0.46), RIG: 19.05 (+0.42), GILD: 101.90 (+1.10), MPC: 103.48 (+2.08), MRO: 29.49 (+0.71), TAL: 41.00 (+0.37), TWTR: 48.50 (+0.55), X: 26.36 (+1.12)
Bristol-Myers Squibb Set to Possibly Rebound After Yesterday's Selloff of 1.37%
Comtex SmarTrend(R) - Mon Feb 09, 4:16PM CST
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $58.65 to a high of $59.75. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $58.76 on volume of 3.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BMY: 60.04 (+0.56)
SmarTrend Watching for Potential Rebound in Shares of Bristol-Myers Squibb After 1.37% Loss
Comtex SmarTrend(R) - Mon Feb 09, 4:16PM CST
Bristol-Myers Squibb (NYSE:BMY) traded in a range yesterday that spanned from a low of $58.65 to a high of $59.75. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $58.76 on volume of 3.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BMY: 60.04 (+0.56)
AstraZeneca Might Need More Than Buzzwords To Bridge The Gap
EP Vantage - Seeking Alpha - Mon Feb 09, 1:57PM CST
It is widely appreciated that life is going to get tougher for AstraZeneca (NYSE: AZN ) over the next couple of years as huge patent expiries bite chunks out of its top line. As the company would have it, however, profits will remain far more...
ACT: 285.37 (+3.71), AZN: 69.96 (+0.20), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17)
3 Medical Advancements You May Be Missing Out On
Motley Fool Staff - Motley Fool - Sun Feb 08, 10:02AM CST
Source: 3D Systems. From 3D printing to next-generation cancer killers, there are some medical innovations that could have an incredible impact on patients. Our Motley Fool analysts explain how these next-generation medical advances could reshape...
BIIB: 391.66 (-0.45), ONVO: 6.34 (+0.07), DDD: 32.81 (+0.40), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), NVS: 102.20 (-0.17), CELG: 115.88 (+0.16)
Which Biotech Stock Should Pfizer, Inc. Buy?
Motley Fool Staff, Brian Orelli, Leo Sun, and George Budwell - Motley Fool - Sun Feb 08, 7:02AM CST
Source: Pfizer. Pfizer is struggling to offset slowing sales tied to expiring patents, and that has some observers thinking that Pfizer remains on the hunt to buy another drugmaker that can spark its growth. Earlier this week, Pfizer announced...
BIIB: 391.66 (-0.45), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), CLDN: 16.45 (-0.05), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16), SGEN: 31.57 (+0.36), GILD: 101.90 (+1.10), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07)
